Cagrilintide Dosing Protocol: Cycling, Frequency & Best Practices

Introduction

Cagrilintide is dosed once a week as a subcutaneous injection, titrated gradually to a target of 2.4 mg in the trials that have studied it. That single sentence covers the core of what the published dosing data shows. Everything beyond that is detail, caveat, and a reminder that this compound is still investigational.

Cagrilintide is a long-acting analog of amylin, a hormone your pancreas releases alongside insulin. Novo Nordisk has studied it both alone and paired with semaglutide in a combination called CagriSema. Because cagrilintide is not approved as a standalone medicine, the dosing information here comes from clinical trial protocols rather than an FDA label. Treat it as background, not instructions.

At TrimRx, we think understanding how a compound is actually dosed in research is the first step toward an honest conversation with your provider. If you want to see whether a personalized, clinician-guided weight program fits your situation, you can take our free assessment quiz.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Is the Standard Cagrilintide Dose?

The standard target dose studied in phase 3 work is 2.4 mg once weekly, given subcutaneously. That figure comes from the REDEFINE 1 trial, where cagrilintide 2.4 mg was tested as monotherapy and as part of CagriSema. Researchers did not start patients at 2.4 mg. They built up to it.

Quick Answer: Cagrilintide is an investigational long-acting amylin analog dosed once weekly by subcutaneous injection. It is not FDA approved as a standalone product.

The 2.4 mg number is not arbitrary. It mirrors the top dose of semaglutide used in obesity (Wegovy® is 2.4 mg weekly), which made the two compounds easy to compare and to combine. Earlier phase 2 work, published by Enebo and colleagues in The Lancet in 2021, tested cagrilintide across a range from 0.3 mg up to 4.5 mg, which is how the field landed on 2.4 mg as the practical target.

How Is Cagrilintide Titrated?

Cagrilintide is titrated upward in steps over about four months to reduce gastrointestinal side effects. A typical trial schedule started low, often around 0.25 mg weekly, then roughly doubled the dose every four weeks until reaching 2.4 mg. This slow ramp is the single most important part of the protocol.

The reason is simple. Amylin analogs slow gastric emptying and act on satiety centers in the brain. Push the dose too fast and the most common result is nausea, sometimes with vomiting. A gradual climb gives the gut time to adapt. In the CagriSema program, both cagrilintide and semaglutide were escalated in parallel on a matched schedule.

If a patient could not tolerate a step up, trial protocols allowed staying at the current dose longer or stepping back down one level. That flexibility is standard for this drug class and is something a prescribing clinician would manage individually.

How Often Is Cagrilintide Injected?

Once a week. Cagrilintide was engineered for a long half-life, reported at roughly seven to nine days, which supports steady once-weekly dosing. That weekly cadence is one of its main selling points compared with older amylin analogs like pramlintide, which required dosing at every meal.

Patients in trials picked one day each week and stayed consistent. The injection goes into subcutaneous fat, typically the abdomen, thigh, or upper arm, with the site rotated to avoid local irritation. Missing a day by a small margin is generally manageable given the long half-life, but the published protocols aimed for the same day each week.

Is There a Cagrilintide Cycling Protocol?

No. There is no evidence-based cycle for cagrilintide, and the trials dosed it continuously rather than in on-and-off blocks. The idea of “cycling” comes from bodybuilding culture around other peptides and does not map onto how amylin analogs were studied.

This matters because weight regain after stopping is a known pattern across the entire GLP-1 and amylin class. When the STEP 1 extension data looked at semaglutide, most lost weight came back within a year of stopping. There is no reason to expect cagrilintide behaves differently. So the honest framing is that this is a continuous therapy in the data we have, not a short burst you cycle off.

If you read a protocol online promoting four-weeks-on, two-weeks-off cagrilintide, understand that no trial supports it.

What Dose Produced the Best Results?

The 2.4 mg weekly dose drove the strongest standalone results, with about 11.8% average body weight reduction over 68 weeks versus 2.3% for placebo in REDEFINE 1. When combined with semaglutide as CagriSema, average loss reached 22.7%, with 60% of participants losing at least 20% of body weight.

Higher does not automatically mean better here. Phase 2 work tested doses up to 4.5 mg, and the efficiency gains flattened while side effects rose. The field settled on 2.4 mg as the balance point between results and tolerability, which is why phase 3 used it.

Key Takeaway: The 2.4 mg weekly dose produced about 11.8% average weight loss as monotherapy over 68 weeks in REDEFINE 1.

How Should Injection Sites Be Managed?

Rotate sites and inject into clean subcutaneous tissue. The abdomen (avoiding a two-inch radius around the navel), the front of the thigh, and the back of the upper arm are the standard locations. Rotating between them lowers the chance of lumps, bruising, or local reactions.

Trial participants were trained to pinch the skin, inject at the recommended angle for the pen or syringe, and dispose of needles safely. None of this is unique to cagrilintide. It is the same technique used for every weekly subcutaneous metabolic drug.

What Side Effects Shape the Dosing Schedule?

Nausea, vomiting, constipation, and diarrhea are the side effects that drive the slow titration. In REDEFINE 1, gastrointestinal symptoms were the most common adverse events and were generally worst during dose escalation, then eased as the body adjusted.

This is exactly why the four-week step schedule exists. The dosing protocol is essentially a side-effect management plan. A clinician watching tolerability decides whether to advance, hold, or reduce. Self-directing this without medical oversight removes the one mechanism that makes the schedule work.

How Does Cagrilintide Dosing Compare to Other Amylin Analogs?

Cagrilintide dosing is far simpler than the older amylin analog pramlintide, which had to be injected before every meal. Cagrilintide replaced that mealtime burden with a single weekly shot, which is the practical reason it moved forward in obesity research.

Pramlintide (Symlin) was approved as an adjunct to insulin and required three or more injections a day timed to food. Adherence suffered as a result. Cagrilintide was designed with chemical modifications that extend its half-life into the week-long range, so one injection covers the same receptor activity that pramlintide needed several daily doses to achieve. This shift from per-meal to once-weekly dosing is the headline advance in amylin pharmacology over the past decade, and it is why a slow weekly titration, rather than meal-by-meal adjustment, defines the modern protocol.

Path Forward with a Guided Program

Cagrilintide is promising but still investigational, and the only responsible way to approach amylin-based therapy today is with a licensed provider. At TrimRX, our clinicians focus on FDA-regulated and compounded options that can be personalized to your medical history, with proper titration and monitoring built in. If you are curious where you stand, the free assessment quiz is a low-pressure starting point, and our team can walk you through what is actually available now versus what is still in trials.

FAQ

What Is the Target Dose of Cagrilintide?

The target dose studied in phase 3 trials is 2.4 mg once weekly by subcutaneous injection, reached through gradual titration over about 16 to 20 weeks.

How Long Does It Take to Titrate up to Full Dose?

Trial schedules took roughly four months, doubling the dose about every four weeks from a low starting point until reaching 2.4 mg, to limit nausea and other gut side effects.

Can I Cycle Cagrilintide on and Off?

No protocol supports cycling. Trials dosed cagrilintide continuously, and weight regain after stopping is common across this drug class, so on-and-off use is not evidence based.

Is Cagrilintide Injected Daily or Weekly?

Weekly. Cagrilintide has a half-life of roughly seven to nine days, which supports once-weekly subcutaneous dosing on the same day each week.

Is Cagrilintide FDA Approved?

Not as a standalone product. It has been studied alone and as part of CagriSema, but all dosing data comes from clinical trials, not an approved label.

Where Do I Inject Cagrilintide?

Into subcutaneous fat in the abdomen, thigh, or upper arm, rotating sites each week to reduce local irritation and bruising.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.